Prostate Cancer

Prostate cancer continues to be the most common newly diagnosed solid tumor in men over 50 years and the second leading cause of cancerspecific mortality.

Julie N. Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses treatment for patients with high-risk metastatic disease following the FDA approval of abiraterone acetate (Zytiga).

Stephen J. Freedland, MD, director, Center for Integrated Research in Cancer and Lifestyle, co-director, Cancer Genetics and Prevention Program, associate director, Faculty Development Samuel Oschin Comprehensive Cancer Institute, professor of surgery, Cedars-Sinai Medical Center, discusses nuanced diet and lifestyle interventions in patients with prostate cancer.

Timothy J. Daskivich, MD, assistant professor of surgery, Cedars-Sinai Medical Center, discusses developing and available imaging modalities in prostate cancer.

Edwin M. Posadas, MD, medical director, Urologic Oncology Program, co-director, Translational Oncology Program, associate professor of medicine, Cedars-Sinai Medical Center, discusses the future of detection in metastatic castration-resistant prostate cancer (mCRPC).

Susan F. Slovin, MD, PhD, discusses the multinational PRONOUNCE study and how the results may affect the treatment of patients with prostate cancer.

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses enzalutamide (Xtandi) for patients with nonmetastatic castration-resistant prostate cancer.

Leonard Gomella, MD, shares his insight on the recent FDA approvals and other ongoing progress in the treatment of patients with prostate cancer.

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the difference between GnRH antagonists and GnRH agonists.

David R. Wise, MD, PhD, assistant professor, Department of Medicine, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses challenges with immunotherapy in prostate cancer.

Investigators looking for a superior means of testing for response to therapy in metastatic castration-resistant prostate cancer said they found the solution in a study of circulating tumor cells.

Leonard Gomella, MD, professor, chair, Department of Oncology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the FDA approval of apalutamide (Erleada) for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

The use of androgen deprivation therapy in prostate cancer is now a well-established treatment regimen but is associated with an increased risk for bone fracture.

Bridget F. Koontz, MD, radiation oncologist, Duke Cancer Institute, discusses the next steps for the phase II trial of 6 months of androgen deprivation therapy/abiraterone acetate (Zytiga) plus prednisone and definitive radiotherapy for men with intermediate- to high-risk localized prostate cancer.

James Gulley, MD, PhD, chief, Genitourinary Malignancies Branch, and director, Medical Oncology Service at the National Cancer Institute, discusses the take-home message with the combination of olaparib (Lynparza) plus durvalumab (Imfinzi) in metastatic castration-resistant prostate cancer.

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses a multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events in patients with prostate cancer and cardiovascular disease receiving degarelix, a GnRH receptor antagonist, or leuprolide, a GnRH receptor agonist.

The FDA has approved apalutamide (Erleada) for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

David R. Wise, MD, PhD assistant professor in the Department of Medicine, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses the FDA approval of apalutamide (ARN-509) for the treatment of patients with non-metastatic castration-resistant prostate cancer (CRPC).

William K. Oh, MD, discusses treatment with abiraterone versus docetaxel in patients with prostate cancer, other remaining questions in the field, and what role immunotherapy is poised to play.

Bridget F. Koontz, MD, radiation oncologist, Duke Cancer Institute, discusses a phase II trial of 6 months of androgen deprivation therapy/abiraterone acetate (Zytiga) plus prednisone and definitive radiotherapy for men with intermediate- to high-risk localized prostate cancer.

Christopher Sweeney, MBBS, discusses the role of abiraterone for patients with hormone-sensitive prostate cancer, and what physicians should consider when choosing between abiraterone and docetaxel.